Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 16, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 16, 2022Completed
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:June 22, 2023Not yet recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:September 5, 2023Approved for marketing
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:January 5, 2024No longer available
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 18, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:August 14, 2023Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 15, 2022Approved for marketing
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 8, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:July 24, 2023Active, not recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 20, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.